Valuation for Corcept Therapeutics (id:5252 CORT)
Financial Strength
| Name | Current | Vs Industry | Vs History |
|---|---|---|---|
| Trailing P/E | 41.02 |
|
|
| Forward P/E | 29.53 |
|
|
| Price to sales | 8.61 |
|
|
| Price to book | 8.47 |
|
|
| Enterprise to revenue | 7.93 |
|
|
| Enterprise to ebitda | 34.60 |
|
|